Selpercatnib, approved for tumors with RET-activating mutations, has shown efficacy in medullary thyroid cancer and other solid tumors harboring RET fusions, as demonstrated in the Libretto trial. This evidence concerns the gene RET and medullary thyroid gland carcinoma.